198 related articles for article (PubMed ID: 23216692)
1. YAP-Hippo signalling downstream of leukemia inhibitory factor receptor: implications for breast cancer.
Hergovich A
Breast Cancer Res; 2012 Dec; 14(6):326. PubMed ID: 23216692
[TBL] [Abstract][Full Text] [Related]
2. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
3. A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion.
Nouri K; Azad T; Lightbody E; Khanal P; Nicol CJ; Yang X
FASEB J; 2019 Nov; 33(11):12487-12499. PubMed ID: 31431076
[TBL] [Abstract][Full Text] [Related]
4. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker.
Chen D; Sun Y; Wei Y; Zhang P; Rezaeian AH; Teruya-Feldstein J; Gupta S; Liang H; Lin HK; Hung MC; Ma L
Nat Med; 2012 Oct; 18(10):1511-7. PubMed ID: 23001183
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER
Ma S; Tang T; Probst G; Konradi A; Jin C; Li F; Gutkind JS; Fu XD; Guan KL
Nat Commun; 2022 Feb; 13(1):1061. PubMed ID: 35217640
[TBL] [Abstract][Full Text] [Related]
6. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression.
Rashidian J; Le Scolan E; Ji X; Zhu Q; Mulvihill MM; Nomura D; Luo K
Sci Signal; 2015 Feb; 8(363):ra14. PubMed ID: 25670202
[TBL] [Abstract][Full Text] [Related]
7. Deregulation of the Hippo pathway in mouse mammary stem cells promotes mammary tumorigenesis.
Li H; Gumbiner BM
Mamm Genome; 2016 Dec; 27(11-12):556-564. PubMed ID: 27601049
[TBL] [Abstract][Full Text] [Related]
8. Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancer.
Shen J; Cao B; Wang Y; Ma C; Zeng Z; Liu L; Li X; Tao D; Gong J; Xie D
J Exp Clin Cancer Res; 2018 Jul; 37(1):175. PubMed ID: 30055645
[TBL] [Abstract][Full Text] [Related]
9. Arhgef7 promotes activation of the Hippo pathway core kinase Lats.
Heidary Arash E; Song KM; Song S; Shiban A; Attisano L
EMBO J; 2014 Dec; 33(24):2997-3011. PubMed ID: 25425573
[TBL] [Abstract][Full Text] [Related]
10. cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes.
Kim M; Kim M; Lee S; Kuninaka S; Saya H; Lee H; Lee S; Lim DS
EMBO J; 2013 May; 32(11):1543-55. PubMed ID: 23644383
[TBL] [Abstract][Full Text] [Related]
11. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.
Moroishi T; Park HW; Qin B; Chen Q; Meng Z; Plouffe SW; Taniguchi K; Yu FX; Karin M; Pan D; Guan KL
Genes Dev; 2015 Jun; 29(12):1271-84. PubMed ID: 26109050
[TBL] [Abstract][Full Text] [Related]
12. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell.
Plouffe SW; Lin KC; Moore JL; Tan FE; Ma S; Ye Z; Qiu Y; Ren B; Guan KL
J Biol Chem; 2018 Jul; 293(28):11230-11240. PubMed ID: 29802201
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
Kim M; Kim T; Johnson RL; Lim DS
Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
[TBL] [Abstract][Full Text] [Related]
14. A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis.
Azad T; Janse van Rensburg HJ; Lightbody ED; Neveu B; Champagne A; Ghaffari A; Kay VR; Hao Y; Shen H; Yeung B; Croy BA; Guan KL; Pouliot F; Zhang J; Nicol CJB; Yang X
Nat Commun; 2018 Mar; 9(1):1061. PubMed ID: 29535383
[TBL] [Abstract][Full Text] [Related]
15. The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα.
Britschgi A; Duss S; Kim S; Couto JP; Brinkhaus H; Koren S; De Silva D; Mertz KD; Kaup D; Varga Z; Voshol H; Vissieres A; Leroy C; Roloff T; Stadler MB; Scheel CH; Miraglia LJ; Orth AP; Bonamy GM; Reddy VA; Bentires-Alj M
Nature; 2017 Jan; 541(7638):541-545. PubMed ID: 28068668
[TBL] [Abstract][Full Text] [Related]
16. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
[TBL] [Abstract][Full Text] [Related]
17. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
19. The Hippo pathway is controlled by Angiotensin II signaling and its reactivation induces apoptosis in podocytes.
Wennmann DO; Vollenbröker B; Eckart AK; Bonse J; Erdmann F; Wolters DA; Schenk LK; Schulze U; Kremerskothen J; Weide T; Pavenstädt H
Cell Death Dis; 2014 Nov; 5(11):e1519. PubMed ID: 25393475
[TBL] [Abstract][Full Text] [Related]
20. Hippo/MST blocks breast cancer by downregulating WBP2 oncogene expression via miRNA processor Dicer.
Lim SK; Tabatabaeian H; Lu SY; Kang SA; Sundaram GM; Sampath P; Chan SW; Hong WJ; Lim YP
Cell Death Dis; 2020 Aug; 11(8):669. PubMed ID: 32820148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
